<DOC>
	<DOCNO>NCT02053350</DOCNO>
	<brief_summary>The aim study test efficacy alanyl-glutamine supplementation treatment C. difficile infection . We hypothesize alanyl-glutamine give standard antibiotic treatment C. difficile infection decrease diarrhea , mortality recurrent disease .</brief_summary>
	<brief_title>Efficacy Study Alanyl-glutamine Supplementation Treatment C. Difficile Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Adult either gender , 18 year old , C. difficile infection ( CDI ) Diarrhea associate C. difficile positive stool assay Within 48 hour receive either metronidazole mildmoderate disease vancomycin severe uncomplicated disease Admitted hospital time enrollment Ability provide inform consent Have understanding study procedure Ability comply study procedure entire length study Hypotension shock Megacolon moderate severe ileus Acute abdomen Severe leukocytosis ( WBC &gt; 20,000 cell /ÂµL ) Admission intensive care unit enrollment Inability tolerate oral medication Other know etiology diarrhea ( e.g . enteric pathogen , intestinal disease ) Inflammatory bowel disease ( e.g . Crohn 's disease , ulcerative colitis ) Enrollment another investigational drug trial Currently receive alternative treatment CDI ( e.g . antibiotic metronidazole vancomycin ; probiotic ; immunoglobulin therapy ; fecal transplant ) Pregnancy Unavailable followup visit Life expectancy &lt; 6 month Chronic liver disease subject without know liver disease , ALT &gt; 3x normal Chronic kidney disease subject without know kidney disease , estimate Creatinine clearance &lt; 30 ml/min , even rehydration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Clostridium difficile</keyword>
	<keyword>glutamine</keyword>
	<keyword>diarrhea</keyword>
	<keyword>alanyl-glutamine</keyword>
</DOC>